Middle cerebral artery peak systolic velocity monitoring of fetal anemia during chemotherapy in pregnancy.
chemotherapy
fetal anemia
middle cerebral artery peak systolic velocity
pregnancy
Journal
Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
revised:
19
11
2023
received:
04
10
2023
accepted:
23
11
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
aheadofprint
Résumé
Chemotherapy during pregnancy can increase the risk of fetal anemia. Severe fetal anemia can lead to the development of hydrops fetalis and potentially fetal demise. Hence, it is imperative to implement consistent monitoring methods in the context of chemotherapy treatment. This study aimed to diagnose and monitor fetal anemia using middle cerebral artery peak systolic velocity (MCA-PSV) as a diagnostic tool during chemotherapy in pregnant women. The study employed a prospective analysis involving a case series of 15 patients diagnosed with cancer during pregnancy and subsequently underwent chemotherapy. MCA-PSV was used to identify fetal anemia. The patients were scheduled for ultrasound examinations of the MCA-PSV. The first examination was performed on the same day as the administration of chemotherapy, while the second occurred on the 10th day after chemotherapy. The measurement technique used in the study was based on the methodology proposed by Mari and Barr. The multiples of the median were calculated using the calculators provided by Medicina Fetal Barcelona. Based on these values anemia severity was determined. When moderate or severe anemia was identified, chemotherapy was individually modified. Additionally, a blood count analysis was conducted immediately after the delivery of the newborn. Five patients were diagnosed with fetal or newborn anemia. With MCA-PSV, we identified moderate fetal anemia in two patients and severe fetal anemia in one. The complete blood count testing of newborns revealed mild anemia in three patients. One case was unrelated to chemotherapy-induced anemia. During treatment, fetal anemia did not corelate with maternal anemia. In four cases of anemia the combination of cisplatin and iphosphamide was used as a chemotherapy agent. No anemia was observed in other drug combinations. Our findings suggest that MCA-PSV is a reliable method for identifying anemia and should be included in the treatment protocol for chemotherapy-induced fetal anemia.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Third Medical Faculty, Charles University in Prague
Informations de copyright
© 2024 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).
Références
Maggen C, Wolters V, Cardonick E, et al. Pregnancy and cancer: the INCIP project. Curr Oncol Rep. 2020;22(2):17.
Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019;30(10):1601-1612.
de Haan J, Verheecke M, Van Calsteren K, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018;19(3):337-346.
Eibye S, Kjaer SK, Mellemkjaer L. Incidence of pregnancy-associated cancer in Denmark, 1977-2006. Obstet Gynecol. 2013;122(3):608-617.
Marnitz S, Köhler C, Oppelt P, et al. Cisplatin application in pregnancy: first in vivo analysis of 7 patients. Oncology. 2010;79(1-2):72-77.
Van Calsteren K, Verbesselt R, Ottevanger N, et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand. 2010;89(10):1338-1345.
Esposito S, Tenconi R, Preti V, Groppali E, Principi N. Chemotherapy against cancer during pregnancy: a systematic review on neonatal outcomes. Medicine (Baltimore). 2016;95(38):e4899.
Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283-291.
Barr JJ, Mari G. Cerebral blood flow velocity waveforms and fetal anemia. In: Maulik D, Lees CC, eds. Doppler Ultrasound in Obstetrics and Gynecology. Springer International Publishing; 2023:297-311.
Moise KJ. The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia. Am J Obstet Gynecol. 2008;198(2):161.e1-161.e4.
Imbar T, Lev-Sagie A, Cohen S, Yanai N, Yagel S. Diagnosis, surveillance, and treatment of the anemic fetus using middle cerebral artery peak systolic velocity measurement. Prenat Diagn. 2006;26(1):45-51.
Mari G, Deter RL, Carpenter RL, et al. Non-invasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the blood velocity in anemic fetuses. N Engl J Med. 2000;342(1):9-14.
Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Mari G, Norton ME, et alSociety for Maternal-Fetal Medicine (SMFM) clinical guideline #8: the fetus at risk for anemia-diagnosis and management. Am J Obstet Gynecol. 2015;212(6):697-710.
Amant F, Halaska MJ, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer. 2014;24(3):394-403.
Mari G, Abuhamad AZ, Cosmi E, Segata M, Altaye M, Akiyama M. Middle cerebral artery peak systolic velocity: technique and variability. J Ultrasound Med. 2005;24(4):425-430.
Halaska MJ, Komar M, Vlk R, et al. A pilot study on peak systolic velocity monitoring of fetal anemia after administration of chemotherapy during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2014;174:76-79.
Ramirez MM, Litton J, Theriault RL, Mastrobattista JM. P32.08: fetal anemia screening using MCA velocities in women receiving chemotherapy during pregnancy. Ultrasound Obstet Gynecol. 2008;32(3):422.
Fruscio R, Villa A, Chiari S, et al. Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: a series of nine cases and literature review. Gynecol Oncol. 2012;126(2):192-197.
Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087.
Bernardini F, Ferrandina G, Ricci C, et al. Neoadjuvant chemotherapy in pregnant patients with cervical cancer: a monocentric retrospective study. Curr Oncol. 2022;29(8):5702-5714.
Huang H, Quan Y, Qi X, Liu P. Neoadjuvant chemotherapy with paclitaxel plus cisplatin before radical surgery for locally advanced cervical cancer during pregnancy. Medicine (Baltimore). 2021;100(32):e26845.
Köhler C, Oppelt P, Favero G, et al. How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy. Am J Obstet Gynecol. 2015;213(2):206.e1-206.e5.
Prefumo F, Fichera A, Fratelli N, Sartori E. Fetal anemia: Diagnosis and management. Best Pract Res Clin Obstet Gynaecol. 2019;58:2-14.
Oepkes D, Adama van Scheltema P. Intrauterine fetal transfusions in the management of fetal anemia and fetal thrombocytopenia. Semin Fetal Neonatal Med. 2007;12(6):432-438.
World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. World Health Organization; 2011 Accessed August 22, 2023. https://apps.who.int/iris/handle/10665/85839